Here’s why a Florida company recalled its male sexual enhancement drugs sold on Amazon

The reason the FDA told Stop Clopez to recall Schwinnng capsules, marketed as a “male sexual enhancement dietary supplement,” has nothing to do with whether or not they work. In fact, it’s because they have an active ingredient that might make them work.

“The Schwinnng products contain Nortadalafil, which may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may cause a significant drop in blood pressure that may be life threatening,” the company-written, FDA-posted recall notice states. “People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Among the adult male population, who are most likely to use this product, adult males who use nitrates for cardiac conditions are most at risk.”

The FDA’s original warning about Schwinnng, in December, explained: “Nortadalafil is structurally similar to tadalafil, the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction. FDA approval of Cialis is restricted to use under the supervision of a licensed health care professional.”

One lot Schwinnng capsules have been recalled.
One lot Schwinnng capsules have been recalled.

What’s recalled is lot No. 2108 of 10-count capsule packs carrying an expiration of “10/2024.” They were sold on Amazon.

Stop Clopez wants refund requests to include the blister pack foil with any capsules left, a receipt and return address.

State corporation and Broward County property records say Stop Clopez was formed by Camila Lopez in January 2023 and is run out of her Miramar home, 2301 Island Dr.

Questions about this recall can be directed to Lopez at 12clopezl@gmail.com or 786-580-5100 from 7 a.m. to 2 p.m., Eastern time, Monday through Friday.

2301 Island Dr. in Miramar, the headquarters of Stop Clopez.
2301 Island Dr. in Miramar, the headquarters of Stop Clopez.

If you have a problem with any drug, tell a medical professional. Then tell the FDA’s MedWatch reporting system either online or by downloading a form and faxing it to 800-322-0178.